Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer
ARCHIVES OF GYNECOLOGY AND OBSTETRICS, cilt.288, sa.6, ss.1399-1403, 2013 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 288 Sayı: 6
- Basım Tarihi: 2013
- Doi Numarası: 10.1007/s00404-013-2924-7
- Dergi Adı: ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1399-1403
- Anahtar Kelimeler: Neoadjuvant chemotherapy, Ovarian cancer, Optimal cytoreduction, Survival, CARCINOMA, DEBULKING, DISEASE
- Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet
Özet
To evaluate results of neoadjuvant chemotherapy (NACT) following debulking surgery in patients with extensive metastatic disease and/or poor medical performance